These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 19422458)
1. Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. Varadi K; Rottensteiner H; Vejda S; Weber A; Muchitsch EM; Turecek PL; Ehrlich HJ; Scheiflinger F; Schwarz HP J Thromb Haemost; 2009 Jul; 7(7):1134-42. PubMed ID: 19422458 [TBL] [Abstract][Full Text] [Related]
2. Preclinical testing of human recombinant von Willebrand factor: ADAMTS13 cleavage capacity in animals as criterion for species suitability. Muchitsch EM; Dietrich B; Rottensteiner H; Auer W; Nehrbass D; Gritsch H; Ehrlich HJ; Turecek PL; Schwarz HP Semin Thromb Hemost; 2010 Jul; 36(5):522-8. PubMed ID: 20632249 [TBL] [Abstract][Full Text] [Related]
3. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Pruss CM; Notley CR; Hegadorn CA; O'Brien LA; Lillicrap D Br J Haematol; 2008 Nov; 143(4):552-8. PubMed ID: 18986390 [TBL] [Abstract][Full Text] [Related]
4. The co-influence of VWD type 2B/2M mutations in the A1 domain and platelet GPIbα on the rate of cleavage to VWF by ADAMTS13. Ma Z; Su J; Zhang J; Ling J; Yin J; Bai X; Ruan C Thromb Res; 2015 Nov; 136(5):987-95. PubMed ID: 26345337 [TBL] [Abstract][Full Text] [Related]
5. High shear dependent von Willebrand factor self-assembly fostered by platelet interaction and controlled by ADAMTS13. Kragh T; Napoleone M; Fallah MA; Gritsch H; Schneider MF; Reininger AJ Thromb Res; 2014 Jun; 133(6):1079-87. PubMed ID: 24681085 [TBL] [Abstract][Full Text] [Related]
6. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Raife TJ; Cao W; Atkinson BS; Bedell B; Montgomery RR; Lentz SR; Johnson GF; Zheng XL Blood; 2009 Aug; 114(8):1666-74. PubMed ID: 19541819 [TBL] [Abstract][Full Text] [Related]
7. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. Rayes J; Hommais A; Legendre P; Tout H; Veyradier A; Obert B; Ribba AS; Girma JP J Thromb Haemost; 2007 Feb; 5(2):321-8. PubMed ID: 17087728 [TBL] [Abstract][Full Text] [Related]
8. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy. Chung MC; Popova TG; Jorgensen SC; Dong L; Chandhoke V; Bailey CL; Popov SG J Biol Chem; 2008 Apr; 283(15):9531-42. PubMed ID: 18263586 [TBL] [Abstract][Full Text] [Related]
9. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645 [TBL] [Abstract][Full Text] [Related]
10. C2362F mutation gives rise to an ADAMTS13-resistant von Willebrand factor. Casonato A; Pontara E; Battiston M; Morpurgo M; Cattini MG; Casarin E; Saga G; Daidone V; De Marco L Thromb Haemost; 2013 Jun; 109(6):999-1006. PubMed ID: 23446343 [TBL] [Abstract][Full Text] [Related]
11. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL J Blood Med; 2022; 13():649-662. PubMed ID: 36405429 [TBL] [Abstract][Full Text] [Related]
12. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. Anderson PJ; Kokame K; Sadler JE J Biol Chem; 2006 Jan; 281(2):850-7. PubMed ID: 16286459 [TBL] [Abstract][Full Text] [Related]
13. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13]. Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599 [TBL] [Abstract][Full Text] [Related]
14. Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro. Wang A; Liu F; Dong N; Ma Z; Zhang J; Su J; Zhao Y; Ruan C Thromb Res; 2010 Oct; 126(4):e260-5. PubMed ID: 20705333 [TBL] [Abstract][Full Text] [Related]
15. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease. Cao W; Sabatino DE; Altynova E; Lange AM; Casina VC; Camire RM; Zheng XL J Biol Chem; 2012 Sep; 287(39):32459-66. PubMed ID: 22854959 [TBL] [Abstract][Full Text] [Related]
16. A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13. Zhang J; Ma Z; Dong N; Liu F; Su J; Zhao Y; Shen F; Wang A; Ruan C PLoS One; 2011; 6(7):e22157. PubMed ID: 21779388 [TBL] [Abstract][Full Text] [Related]
17. Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. Lu RN; Yang S; Wu HM; Zheng XL J Thromb Haemost; 2015 Jun; 13(6):1064-72. PubMed ID: 25782102 [TBL] [Abstract][Full Text] [Related]
18. The WXXW motif in the TSR1 of ADAMTS13 is important for its secretion and proteolytic activity. Ling J; Su J; Ma Z; Ruan C Thromb Res; 2013 Jun; 131(6):529-34. PubMed ID: 23683325 [TBL] [Abstract][Full Text] [Related]
19. Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W. Pruss CM; Golder M; Bryant A; Hegadorn C; Haberichter S; Lillicrap D J Thromb Haemost; 2012 May; 10(5):940-50. PubMed ID: 22372972 [TBL] [Abstract][Full Text] [Related]
20. Mechanistic studies on ADAMTS13 catalysis. Di Stasio E; Lancellotti S; Peyvandi F; Palla R; Mannucci PM; De Cristofaro R Biophys J; 2008 Sep; 95(5):2450-61. PubMed ID: 18502798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]